DETECTION OF ALPHA-SYNUCLEIN IN BIOPSIES AND SURGICAL RESECTIONS OF PERIPHERAL **ORGANS IN PATIENTS WITH ISOLATED REM SLEEP BEHAVIOR DISORDER**

G. Mayà^{1,2}, I Aldecoa^{2,3}, N Vidal³, Gaig C¹, Santamaria J¹, Serradell M¹, L. Molina^{2,4}, Gelpi E⁵, Iranzo A¹

Virtual Congress 1. Unidad de Sueño, Servicio de neurología, Hospital Clínic de Barcelona, Barcelona, España 2.Banco de tejidos neurológicos del Biobanco, Hospital Clínic de Barcelona-IDIBAPS, Barcelona, España 3. Servicio de Anatomia Patológica, Hospital Clínic de Barcelona, Barcelona, España 4. Unidad de Alzhéimer y otros trastornos cognitivos, Servicio de neurología, Hospital Clínic de Barcelona, Barcelona, España 5. Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria

INTRODUCTION

Isolated REM sleep behavior disorder (IRBD) is a parasomnia that confers a 91% risk at 15-years of follow up of developing a sinucleinopathy (approximately 45% Parkinson's disease, 45% dementia with Lewy bodies and 5% Multisystem Atrophy)¹, characterized by brain alpha-synuclein (a-Syn) deposits.

Recent studies in IRBD have shown the presence of pathological a-Syn also in the cerebrospinal fluid with high sensitivity (90.4%) and specificity (90%)². In addition, immunohistochemistry with antibodies against phosphorylated synuclein (p-Syn), targeting pathologic a-Syn, shows inclusions in the peripheral autonomic nervous system (pANS) of IRBD, but with conflicting results. Prospective studies in IRBD collecting samples from submandibular gland, parotid, labial salivary glands, colon, stomach and skin have shown high specificity (94-100%) but a wide range of sensitivity (24-82%)^{3,4,5,6,7,8}. In a retrospective study with p-Syn using previous surplus samples of the gastrointestinal tract from the clinical practise, 56% of prodromic Parkinson's disease, 50% of Parkinson's disease and up to 26% of controls had pANS pathological inclusions⁹. This study had the advantage to use previous samples and avoid new interventions with potential side effects, but the samples were not obtained with the purpose to assess a-Syn in the autonomic nervous tissue, and this could explain the worse results. Recently, a novel antibody (5G4) against oligomeric pathologic forms of a-Syn (o-Syn) has been used in brain tissues with excellent results but to our knowledge there is no experience in peripheral tissue in IRBD.

Our aim was to assess the presence of phosphorylated a-Syn (p-Syn) and oligomeric a-Syn (o-Syn) in previous surplus gastrointestinal, skin, and urological biopsies/surgical resections of IRBD patients and matched controls.

METHODS

A total of 164 samples (either biopsies- small size- or surgical resections -bigger size-) from 49 polysomnogram (PSG) confirmed RBD patients were retrospectively collected from the Pathology Department archives of the last 25 years (1998-2023) and matched with 161 samples from 122 neurological controls by organ, pathology age and gender (i.e., prostate adenocarcinoma in a 70-year-old man). Immunohistochemistry with antibodies against phosphorylated a-Syn (p-Syn, pSyn64, Wako) and oligomeric a-Syn (o-Syn, 5G4, Roboscreen), were used.

RESULTS

A. IRBD Samples (case biopsies or surgical resections found)


October 4-6, 2023

Peripheral nerve tissue	IRBD (n=164)	Surgical resection (%) Samples with bigger	Genitourinary tract	57 (34.8%)
Gastrointestinal tract	83 (50.6%)	area/size, otherwise are smaller biopsies	Prostate Bladder	49 7
Esophagus	12	44.7%	Kidney	1
Stomach	6			
Duodenum	3			
Small intestine	1		Skin	24 (14.6%)
Blind	1		Face	8
Colon	25	29.8%	Thorax	6
Sigma	23		Arms	1
Straight	6		Legs	5
Anus	4	25.5%	Pelvis	3
Gall bladder	3		Unknown	1

Evaluation of the samples


Positive (+) strict criteria


Missing or slight background (unspecific immunoreactivity) with A, B or C: A) Lewy bodies / coarse aggregates



Positive (+) lax criteria

Positive pattern (A, B or C) but with moderate or severe background






Analysis of IRBD (+) samples by anatomical origin*

Gall bladder 3

B. Analysis by matched samples

General analysis*

	IRBD (n=164)	Controls (n=161)	P-valor
Age at sample (years)	70.6 ± 7.7	70.3 ± 8.1	0.7
Gender (male)	90.9%	89.4%	0.7
Area (mm2)	53.7 ± 81.2	64.8 ± 92.5	0.3
p-Syn (+) lax	23.8%	9.3%	<0.001
p-Syn (+) strict	6.7%	0.6%	0.004
o-Syn (+) lax*	14%	1%	<0.001
o-Syn (+) strict*	10%	1%	<0.001



		o-Syr	n (+)*	p-Syı	า (+)
		Lax	Strict	Lax	Strict
NO A	IRBD	15%	8%	26.5%	3.6%
- Bar	Control	2%	2%	6.3%	0%
¥	Backgroun	d+ 7	7%	4	42%
	IRBD	16%	<u>14%</u>	21.1%	<u>14%</u>
	Control	2%	0%	7%	1.8%
	Backgroun	d+	9%	5.	1%
	IRBD	25%	8%	20.8%	0%
Lit	Control	4%	0%	25%	0%
	Backgroun	d+	6%	7.	9%

Urologic tissue was more frequently (+) as there were a higher percentage of surgical resections, which had a higher positive ratio.

p-Syn (+) in the skin was similar in case and controls +Moderate to severe background

*o-Syn: Only 80 IRBD and 74 control samples have been assessed with 5G4. These results are provisional and shown without decimals

C. Analysis by subjects

	TCSRA (n=49)	Controls(n=122)	P-valor
Number of samples	3.3 ± 2.5 (1-12)	1.3 ± 0.8 (1-8)	<0.001
p-Syn (+) lax	22 (44.9%)	13 (10.7%)	
p-Syn (+) strict	9 (18.4%)	1 (0.8%)	
p-Syn and/or o-Syn (+) lax*	24 (49%)	14 (11.5%)	<0.001
p-Syn and/or o-Syn (+) strict*	15 (30.6%)	2 (1.6)	<0.001

ACKNOWLEDGEMENTS

CONCLUSIONS

Pathological a-Syn can be found in surplus biopsies/surgical resections of patients with IRBD even years before the onset of the parasomnia symptoms with low sensitivity and variable specificity.

The heterogeneity of the tissue (organ, pathology-inflammation) and its processing (fixation, dehydration, paraffin, years from acquisition) hinders to avoid the nonspecific background in the samples and this limits their interpretation.

Strict criteria for positivity of α -synuclein deposits according to the background offers high specificity, but very low sensitivity.

We are indebted to the Biorepositori d'Anatomia Patològica de l'Hospital Clínic de Barcelona and to the IDIBAPS Biobank, integrated in the Spanish National Biobanks Network (PT13/0010/0011), for the sample and data procurement, and to the Xarxa de Bancs de Tumors de Catalunya (XBTC) financed by the Pla Director d'Oncologia de Catalunya.

The 5G4-SYN antibody against oligomeric a-Syn has less background (non-specific immunoreactivity) and could be more specific with a similar low sensitivity.

RT-QuIC techniques are more sensitive and specific for the diagnosis of Synucleinopathies.

<u>The use of antibodies against p-Syn and o-Syn with surplus peripheral tissue for the</u> <u>diagnosis of a synucleinopathy in IRBD probably has not clinical utility.</u>

REFERENCES

1. Iranzo A, Fernández-Arcos A, Tolosa E, Serradell M, Molinuevo JL, Valldeoriola F et al. Neurodegenerative Disorder Risk in Idiopathic REM Sleep Behavior Disorder: Study in 174 Patients. Plos One, 2014 2. Iranzo A, Fairfoul G, Chumbala A, Serradell M, Gelpi E, Vilaseca I et al. Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurol 2021 3. Vilas D, Iranzo A, Tolosa E, Aldecoa I, Berenguer J, Vilaseca I et al. Assessment of α-synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurol 2016 4. Iranzo A, Borrego S, Vilaseca I, Martí C, Serradell M, Sánchez-Valle R et al. α-Synuclein aggregates in labial salivary glands of idiopathic rapid eye movement sleep behavior disorder. Sleep, 2018 5. Fernández-Arcos A, Vilaseca I, Aldecoa I, Serradell M, Tolosa E, Santamaría J et al. Alpha-synuclein aggregates in the parotid gland of idiopathic REM sleep behavior disorder. Sleep Med, 2018. 6. Sprenger F, Stefanova N, Gelpi E, Seppi K, Navarro-Otano J, Offner F et al. Enteric nervous system α-synuclein immunoreactivity in idiopathic REM sleep behavior disorder. Neurology, 2015 7. Doppler K, Jentschke HM, Schulmeyer L, Vadasz D, Janzen A, Luster M et al. Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease. Acta Neuropathol 2017 8. Al-Qassabi A, Tsao TS, Racolta A, Kremer T, Cañamero M, Belousov A et al. Immunohistochemical Detection of Synuclein Pathology in Skin in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinsonism. Mov Dis 2021 9. Stokholm MG, Danielsen EH, Hamilton-Dutoit SJ, Borghammer P. Pathological a-Synuclein in Gastrointestinal Tissues from Prodromal Parkinson Disease Patients. Ann Neurol, 2016

https://esleepeurope.eu/